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The role of intracellular messengers in the stimulatory effect of angiotensin II on angiotensinogen synthesis and secretion in hepatccytes was exam- 
ined. Angiotensinogen secretion was not influenced by modulators of intracellular calcium (cahnidaxolium, A 23187, Bay K 8644, methoxamine). 
In contrast, agents decreasing intracellular CAMP (angiotensin II, guanfacine) stimulated, andthose increasing CAMP (isoproterenol, glucagon, 
forskolin) depressed angiotensinogen secretion. An inverse relationship was also observed between CAMP and angiotensinogen mRNA. Pretreat- 
ment of hepatocytes with pertussis toxin abolished the stimulation by angiotensin II. It is concluded that angiotensin II-induced stimulation of 
angiotensinogen synthesis is initiated by inhibition of adenylate cyclase. 
Angiotensinogen synthesis; Angiotensin II; Pertussis toxin; Adenosine monophosphate, 3, S-cyclic; (Rat hepatocyte) 
1. INTRODUCTION 
The glycoprotein angiotensinogen serves as the sub- 
strate of renin (EC 3.4.23.15) for the generation of 
angiotensin I, which is subsequently converted to angio- 
tensin II. The rate of angiotensinogen secretion by the 
liver has a direct influence on steady-state concentra- 
tions of angiotensin II in the circulation [l]. Converse- 
ly, angiotensin II seems to have a stimulatory effect on 
angiotensinogen secretion, at least under pathophysio- 
logical conditions [2,3]. This response to exogenous 
angiotensin II, which may reflect the effector limb of a 
positive feedback loop, has also been observed in the 
isolated liver [4,5], and isolated hepatocytes [5,6]. 
[U-i4C]leucine was added per flask for the estimation of protein syn- 
thesis and secretion. At various time intervals, aliquots were taken for 
the estimation of albumin, angiotensinogen, and leucine-labelled pro- 
teins in the cell-free supernatant and of angiotensinogen mRNA, 
CAMP, and leucine-labelled proteins in the cell pellet. 
Experimental additions to hepatocyte incubations were made in a 
single volume of less than 0.5 ml, except for angiotensin II, which was 
added by continuous infusion, since this peptide undergoes rapid de- 
gradation in hepatocyte suspensions [5,9]. Actual concentrations of 
angiotensin II in the incubation medium were estimated by radioim- 
munoassay [5]. 
2.2. Pertussis toxin treatment 
We have previously shown in isolated hepatocytes 
that angiotensin II-induced secretion of angioten- 
sinogen is preceded by an increase in angiotensinogen 
mRNA [7]. In the present study, we examined which of 
the known signal transduction pathways for angioten- 
sin II in hepatocytes mediates this response. 
2. MATERIALS AND METHODS 
Pertussis toxin was purified from the culture broth of Bordetella 
pertussis (kindly donated by Dr F. Blackkolb, Behringwerke, Mar- 
burg, FRG) as described by Sekura [lo], except hat ammonium sul- 
fate precipitation of the purified toxin was omitted. Hepatocyte sus- 
pensions were exposed to pertussis toxin (0.5 cg/mI) for 3 h, and sub- 
sequently for 1 h to 90 nM angiotensin II (or vehicle). Immediately 
before and after 1 h of angiotensin II exposure, samples were taken 
for the estimation of angiotensinogen mRNA. Incubations without 
pertussis toxin and/or without angiotensin II served as controls. 
Treatment of intact cells with pertussis toxin led to an almost com- 
plete ( z 958’0) ADP-ribosylation of the approximately 40 kDa toxin 
substrate(s) present in hepatocyte membranes, as assessed by 
[“P]ADP-ribosylation of membrane proteins using pert&s toxin 
and [3ZP]NAD. 
2.1. Preparation of hepatocytes and incubation conditions 
Hepatocytes were isolated from livers of male Sprague-Dawley rats 
weighing 200-280 g by the collagenase technique of Seglen [8] with 
several modifications described previously [5,9]. Cells were suspended 
in minimal essential medium (MEM) containing Earle’s salts to a den- 
sity of 1.5 x l$ cells/ml, and incubated in 30 ml aliquots in 400 ml 
round-bottom flasks under an atmosphere of OZ/COZ (95 : 5) at 37°C 
and 60/min oscillations. At the beginning of incubation, 0.125 &i of 
2.3. Analytical methods 
Angiotensinogen concentrations were determined by incubating ali- 
quots with an excess of hog renin and estimation of angiotensin I by 
radioimmunoassay [5]. 
Angiotensinogen mRNA was measured by liquid hybridization 
with labelled angiotensinogen cRNA as described by Hellmann et al. 
[l I]. The plasmid used for cell-free transcription of “P-1abelled anti- 
sense and unlabelled sense angiotensinogen mRNA was pRAN 2, con- 
taining the vector pspt 18, an angiotensinogen 712 bp BamHI cDNA 
fragment, and the promoters for SP 6 and T 7 polymerases. For de- 
tails see [8,11]. 
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Albumin was measured with a radioimmunoassay [PI. 
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Incorporation of [‘4C]leucine into secreted and cellular protein was 
measured as described [PI. 
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For the estimation of CAMP, 1 ml aliquots of hepatocyte suspen- 
sion were lysed by the addition of 2 ml of ethanol. Following cen- 
trifugation at 200 x g for 3 min, the pellet was reextracted with 1 ml 
of 60% ethanol, the supernatants were combined, centrifuged at 
2000 x g for 15 min at 4”C, and evaporated at 60°C in a stream of 
nitrogen, the residue dissolved in 50 mM phosphate buffer, pH 6.8, 
and CAMP measured by radioimmunoassay. 
2.4. Materials 
The plasmid used for the cell-free transcription of the hybridization 
probe was a gift from Drs Ganten and Hellmann, Dept. of Pharma- 
cology, Heidelberg. “P-1abelled nucleotides were from DuPont de 
Nemour (Bad Homburg, FRG). A23187 and glucagon were from 
Sigma (Munich), other peptides from Bachem (Switzerland). 
Calmidazolium was obtained from Janssen Pharmaceuticals (Neuss), 
[‘4C]leucine was from NEN (Dreieich), and [“‘I]iodide, as well as the 
CAMP radioimmunoassay kit from Amersham Buchler (Braun- 
schweig, FRG). Bay K 8644 was a gift from Dr R. Gross (Bayer AG, 
Leverkusen), TPA from Dr Hecker (Deutsches Krebsforschungszen- 
trum, Heidelberg). All other reagents were of analytical grade or the 
highest purity available. 
2.5. Evaluation of data 
Data are expressed as mean values f S.E.M. Experimental groups 
were compared by ANOVA and, if applicable, by Bonferoni’s 
method. 
3. RESULTS 
3.1. Modulation of second messengers and 
angiotensinogen secretion 
The major signal transduction pathway by which 
angiotensin II influences intracellular functions in 
hepatocytes eems to be the activation of phospholipase 
C, release of both inositol trisphosphate and diacyl- 
glycerol, and the subsequent increase in intracellular 
calcium and activation of the Ca’+-activated, phospho- 
lipid-dependent protein kinase (protein kinase C), re- 
spectively [12,13]. In addition, angiotensin II has been 
shown to inhibit adenylate cyclase and reduce intra- 
cellular CAMP [14,15]. To identify the pathway that 
mediates the stimulation of angiotensinogen synthesis 
and secretion, hepatocytes were exposed to agents that 
mimic or modulate the availability of intracellular 
messengers. As angiotensinogen secretion starts to in- 
crease 2-3 h after exposure to angiotensin II, angioten- 
sinogen secretion was measued during the 4th hour of 
incubation. The results are summarized in table 1. 
Angiotensin II (90 nM) induced an almost 2-fold in- 
crease in angiotensinogen secretion. Various modifiers 
of intracellular calcium concentration or availability 
such as the cur-adrenoceptor agonist, methoxamine, the 
calcium ionophore, A23187, the calcium channel 
agonist, Bay K 8644, and the calmodulin antagonist, 
calmidazolium, failed to influence angiotensinogen se- 
cretion. Oleylacetylglycerol, which mimicks endo- 
genous diacylglycerol, had no effect on angioten- 
sinogen secretion in concentrations up to 10 ,uM, when 
given alone or in combination with A23187, whereas 
the protein kinase C activator, TPA (12-O-tetradeca- 
noylphorbol-13-acetate), reduced angiotensinogen se- 
cretion by 33%. 
302 
Table 1 
Modulation of intracellular messengers and angiotensinogen 
Agent Angiotensinogen secretion 
(ng AI/mg wet wt./h) 
Control Experimental % change 
Angiotensin II (90 nM) 106* 7 209t 9 +97* 
A23187 ( 5pM) 142& 15 135+ 15 -9 
Bay K 8644 ( 5rM) 238 f 14 253k 7 +6 
calmidazolium ( 5rM) 137* 10 126? 7 -8 
methoxamine (10 cM) 98zt 3 96+ 9 -2 
OAG (10 rM) 121f 9 136+ 8 + 12 
OAG and A23187 (lo/5 ,uM) 107 f 10 114+ 7 +6 
TPA ( 0.2rM) 1851t 6 124* 12 -33* 
forskolin ( 1rM) 185& 6 119rt 8 - 36’ 
glucagon (50 nM) 192zt 10 91* 3 -53** 
isoprot + IBMX ( 5/M) 112z.t 3 71+ 4 -37’ 
guanfacine (10 PM) 107* 5 170+ 11 + 59** 
Agents have been added at time zero, and angiotensinogen secretion 
was measured uring the 4th hour in these groups (experimental) in 
comparison to the respective control incubations (control). OAG = 
oleylacetylglycerol; IBMX = isobutylmethylxanthine; isoprot = iso- 
Proterenol; most agents have been examined at 2-3 concentrations. 
Only the highest cont. are listed. Mean values + SEM of 5-6 separate 
*PI 0.05; **F%o.o1 
experiments 
In contrast to calcium-modulating agents, all sub- 
stances affecting intracellular CAMP concentrations 
modified angiotensinogen secretion. Thus, iso- 
proterenol (in combination with the phosphodiesterase 
inhibitor, isobutylmethylxanthine), glucagon and for- 
skolin reduced angiotensinogen secretion by 37%, 53% 
and 36%, respectively, whereas the az-adrenoceptor 
agonist, guanfacine, increased angiotensinogen secre- 
tion by 59%. 
All experimental additions described had no in- 
fluence on [14C]leucine incorporation into cellular or 
secreted protein, nor did they affect albumin secretion 
during the observation period (data not shown). 
3.2. Effect of glucagon and angiotensin II on 
angiotensinogen mRNA 
The opposing effects of agents stimulating or inhib- 
iting CAMP formation on angiotensinogen secretion are 
also apparent at the mRNA level. As shown in fig. 1, 
glucagon (5 and 50 nM) reduces angiotensinogen 
mRNA from 5.7 + 0.21 to 4.8 + 0.23, and 
3.7 + 0.14 pg mRNA/pg total RNA, respectively, dur- 
ing 2 h of exposure, whereas angiotensin II (9 and 
90 nM) increased angiotensinogen mRNA to 7.8 * 0.3 
and 10.1 f 0.5 pg/pg RNA, respectively. 
3.3. Relationship between angiotensinogen synthesis 
and intracellular CAMP 
Direct evidence for an inverse relationship between 
intracellular CAMP and angiotensinogen synthesis and 
secretion is given in fig. 1. Within 5 min after the addi- 
tion of angiotensin II (9 and 90 nM) CAMP was (tran- 
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pg mRNA/ug RNA kinase C, since the phorbol ester, TPA, a potent ac- 
tivator of protein kinase C, significantly reduced the 
rate of angiotensinogen secretion. However, this inhibi- 
tion runs counter to the observed stimulation of angio- 
tensinogen secretion by angiotensin II, if angiotensin II 
were assumed to control angiotensinogen synthesis 
through this pathway (see, however, below). 
Fig.1. Effects of glucagon and angiotensin II on CAMP, angioten- 
sinogen mRNA and secretion. Glucagon (Glu) or angiotensin II (AH) 
were added at time zero to hepatocytes as described in section 2. Mean 
values f SEM of experiments (*P<O.O5; **PsO.Ol; ***P~O.OOl). 
siently) reduced by 24% and 42%) respectively, whereas 
glucagon (5 and 50 nM) produced the expected increase 
in CAMP, which, at 5 min, was about 3- and 6-fold, re- 
spectively. 
This relationship was further studied in pertussis 
toxin-treated hepatocytes (fig.2). In control hepato- 
cytes, angiotensinogen mRNA concentration was 
5.27 + 0.15 pg/pg total RNA at time zero, and fell 
slightly to 5.0 + 0.14 and 4.6 f 0.06 pg/pg RNA at 3 
and 4 h of incubation, respectively. Addition of 90 nM 
angiotensin II at 3 h led to an increase from 4.9 + 0.1 to 
6.6 f 0.43 pg mRNA (P<O.Ol) within 60 min, whereas 
in hepatocytes pretreated for 3 h with 0.5 gg/ml of per- 
tussis toxin, the increase in angiotensinogen mRNA by 
angiotensin II was completely blocked. 
4. DISCUSSION 
The activation of phospholipase C with the subse- 
quent increase in inositol triphosphate and cytosolic 
calcium is generally considered the major transmem- 
brane signalling system for angiotensin II in hepato- 
cytes [ 12,131. Surprisingly, all pharmacological manip- 
ulations of intracellular calcium failed to influence 
angiotensinogen secretion. Although intracellular 
calcium was not measured in these experiments, it is un- 
likely that no changes in intracellular calcium 
homeostasis occurred with any of the agents used. 
Another consequence of the activation of phospho- 
lipase C by angiotensin II is the liberation of diacyl- 
glycerol and activation of protein kinase C. The failure 
of oleylacetylglycerol to affect angiotensinogen secre- 
tion may be due to insufficient activation of protein 
The other transmembrane signalling pathway for 
angiotensin II in hepatocytes is the coupling of angio- 
tensin II receptors to adenylate cyclase through an in- 
hibitory Gi-protein [14,15]. This type of coupling has 
also been demonstrated in hepatocytes for 
cuz-adenoceptor agonists like guanfacine [ 141. The data 
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Fig.2. Pertussis toxin prevents the response of angiotensinogen 
mRNA to angiotensin II. Hepatocytes in groups C and D were pre- 
treated for 3 h with 0.5 gg/ml pertussis toxin (PT). Angiotensin II 
(AII) 90 nM was added at 3 h to groups B and D. Control hepatocytes 
received no addition (group A). Angiotensinogen mRNA was 
measured at 3 (left, light-shaded columns) and 4 h (right, dark col- 
umns) and expressed as pg mRNA/pg of total RNA. There were no 
significant differences in total RNA (**P10.01 for the difference to 
values before AII). 
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of table 1 and fig. 1 suggest that manipulations of the in- 
tracellular concentration of CAMP induce an inverse 
change in angiotensinogen synthesis and secretion. 
Since angiotensin II induces both a decrease in CAMP 
and an increase in angiotensinogen mRNA, it appears 
possible that inhibition of adenylate cyclase by angio- 
tensin II rather than its calcium-mobilizing effect is the 
initiating action by which angiotensin II stimulates 
angiotensinogen synthesis. This view is strongly sup- 
ported by the observation that pertussis toxin complete- 
ly abolishes this effect of angiotensin II, since it has 
been demonstrated in several laboratories that, in 
hepatocytes, the Q-protein of the adenylate cyclase 
complex, but not the G-protein coupling angiotensin II 
receptors to phospholipase C is pertussis toxin-sensitive 
(e.g. [15-171). This interpretation would also help to ex- 
plain why activation of protein kinase C by TPA in- 
hibits angiotensinogen secretion, as several aboratories 
have reported that activation of protein kinase C by 
TPA induces phosphorylation and inactivation of the 
G-protein [18-201. This would tend to increase 
adenylate cyclase activity and, consequently, decrease 
angiotensinogen synthesis. 
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